Ontology highlight
ABSTRACT:
PROVIDER: PRJNA507901 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR8270620_1.fastq.gz | Fastqsanger.gz | |||
| SRR8270620_2.fastq.gz | Fastqsanger.gz | |||
| SRR8270630_1.fastq.gz | Fastqsanger.gz | |||
| SRR8270630_2.fastq.gz | Fastqsanger.gz | |||
| SRR8270640_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 62 |
Similar Datasets
Project description:The spread of carbapenemase-producing Enterobacterales (CPE) is emerging as a significant clinical concern in tertiary hospitals and in particular, long-term care facilities with deficiencies in infection control. This study aims to evaluate an advanced matrix-assisted laser desorption/ionization mass spectrometry (A-MALDI) method for the identification of carbapenemases and further discrimination of their subtypes in clinical isolates. The A-MALDI method was employed to detect CPE target proteins. Enhancements were made to improve detectability and mass accuracy through the optimization of MALDI-TOF settings and internal mass calibration. A total of 581 clinical isolates were analyzed, including 469 CPE isolates (388 KPC, 51 NDM, 40 OXA, and 2 GES) and 112 carbapenemase-negative isolates. Clinical evaluation of the A-MALDI demonstrated 100% accuracy and precision in identifying all the collected CPE isolates. Additionally, A-MALDI successfully discriminated individual carbapenemase subtypes (KPC-2 or KPC-3/4; OXA-48 or OXA-181 or OXA-232; GES-5 or GES-24) and also differentiated co-producing carbapenemase strains (KPC & NDM; KPC & OXA; KPC & GES; NDM & OXA), attributed to its high mass accuracy and simultaneous detection capability. A-MALDI is considered a valuable diagnostic tool for accurately identifying CPE and carbapenemase’s subtypes in clinical isolates. It may also aid in selecting appropriate antibiotics for each carbapenemase subtype. Ultimately, we expect that the A-MALDI method will contribute to preventing the spread of antibiotic resistance and improving human public health.
2024-11-26 | PXD058284 | Pride
Project description:This study aims to determine the epidemiology of Enterobacteriaceae resistant to antibiotics of last resort in pregnant women in labour at a tertiary hospital, Pretoria, South Africa. Rectal swabs shall be used to screen for colonisation with CRE and colistin-resistant Enterobacteriales in pregnant women during labour. Carbapenem and colistin-resistant Enterobacterales can cause the following infections: bacteraemia; nosocomial pneumonia; urinary tract infections, and intra-abdominal infections. Due to limited treatment options, infections caused by these multidrug-resistant organisms are associated with a mortality rate of 40-50%. Screening for colonisation of carbapenem-resistant Enterobacteriaceae (CRE) and colistin-resistant Enterobacteriaceae will help implement infection and prevention measures to limit the spread of these multidrug-resistant organisms.
2022-07-20 | GSE208573 | GEO
Project description:Spread and persistence of the glycopeptide-resistant ST1421 Enterococcus faecium clone in a tertiary Hospital in Madrid.
| PRJEB87619 | ENA
Project description:Staphylococcus aureus clonal complex 398 (CC398) isolates colonize livestock and can spread to human contacts. Genetic analysis of isolates epidemiologically associated with human-to-human, but not livestock, transmission in multiple countries and continents identified a common clade that was negative for tet(M) and positive for bacteriophage 3. Another group of human-to-human-transmitted isolates belonged to the common livestock-associated clade but had acquired a unique φ7 bacteriophage. [Data is also available from http://bugs.sgul.ac.uk/E-BUGS-124]
2012-10-29 | E-BUGS-124 | biostudies-arrayexpress
Project description:Hospital Epidemiology of MRSA in a Tertiary Care Hospital in Tanzania
| PRJEB23314 | ENA
Project description:A total of 386 patients were enrolled from May 2019 to May 2022 in TEDA International Cardiovascular Hospital, Tianjin, China. This study was approved by Institutional Review Board (IRB) at TEDA International cardiovascular hospital, Tianjin, china, and informed consent was obtained from all patients recruited in this study. All patients were informed of all the aspects of the study. STEMI refers to designate MI in patients with chest discomfort or other ischaemia symptoms, who develop new ST-segment elevations in two contiguous leads or new bundle branch blocks with ischaemia repolarization patterns as an ST-elevation MI. Patients present without ST-segment elevation were designated as having NSTEMI (13). Patients without ST-segment elevation exert symptoms suggestive of cardiac ischemia without elevated biomarker values can be diagnosed as having UA(5, 13). The inclusion and exclusion criteria of STEMI, NSTEMI and UA patients were according to the guidelines outlined by the 2017 European Society of Cardiology (ESC)(14). The control subjects were recruited from patients that underwent conventional coronary angiography for atypical chest discomfort(15). Finally, 182 patients were included in STEMI group, 80 in NSTEMI group, and 62 in UA group. Additionally, after matching the age and gender, 62 subjects with normal coronary arteries were identified as Control (CON). All treatment and management measures were monitored by the attending physicians. Further, the clinical information was collected, including age, gender, body mass index (BMI), risk factors such as hypertension, diabetes, dyslipidemia, and smoke. The vessel lesion and laboratory data were also collected.
2025-07-14 | PXD056463 | Pride
Project description:Systemic sclerosis (SSc) poses a significant challenge in autoimmunology, characterized by the development of debilitating fibrosis of skin and internal organs. The pivotal role of dysregulated T cells, notably the skewed polarization toward Th2 cells, has been implicated in the vascular damage and progressive fibrosis observed in SSc. In this study, we explored the underlying mechanisms by which cannabinoid receptor 2 (CB2) highly selective agonist HU-308 restores the imbalance of T cells to alleviate SSc. Using a bleomycin-induced SSc (BLM-SSc) mouse model, we demonstrated that HU-308 effectively attenuates skin and lung fibrosis by specifically activating CB2 on CD4+ T cells to inhibit the polarization of Th2 cells in BLM-SSc mice, which was validated by Cnr2-specific-deficient mice. Different from classical signaling downstream of G protein-coupled receptors (GPCRs), HU-308 facilitates the expression of SOCS3 protein and subsequently impedes the IL2/STAT5 signaling pathway during Th2 differentiation. The deficiency of SOCS3 partially mitigated the impact of HU-308. Analysis of a cohort comprising 62 SSc patients and 82 healthy controls revealed an abnormal elevation in the Th2/Th1 ratio in SSc patients. Administration of HU-308 to PBMCs and peripheral CD4+ T cells from SSc patients led to the upregulation of SOCS3, which effectively suppressed the aberrantly activated STAT5 signaling pathway and the proportion of CD4+IL4+ T cells. In conclusion, our findings unveil a novel mechanism by which the CB2 agonist HU-308 ameliorates fibrosis in SSc by targeting and reducing Th2 responses. These insights provide a foundation for future therapeutic approaches in SSc by modulating Th2 responses.
2025-02-27 | GSE261552 | GEO